OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved ...

Health care routinely recommends movement without providing assessment, dosage, progression, and follow-up that turn good ...

GLP-1 drugs first made their mark in diabetes and obesity, but many research efforts are underway to bring such therapies to more indications. Altimmune now has mid-stage clinical trial results ...

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The ...

HealthTap launched a virtual care program to support sleep equipment suppliers and patients using PAP therapy.

Happy Health has received FDA clearance for its wearable ring, which continuously measures blood pressure without a cuff or ...

Cybersecurity leaders discussed how AI-driven cybersecurity attacks pose a new level of risk for hospitals and health systems ...

The Series A round was led by Oak HC/FT, with participation from Norwest, .406 Ventures, Constellation Ventures, Y Combinator ...

Earlier detection is valuable, but it creates a duty that does not end when an alert appears in the electronic health record.

Outro’s funding included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah ...

Diagnostics and drug development startup Arboretum LifeSciences launched with $30 million in financing. Its executives say ...

Shionogi’s IntraBio acquisition brings Aqneursa, a drug approved for treating two rare neurological disorders and the potential to expand to additional indications, both rare and common. It’s Shionogi ...